Cefiderocol appears promising, as it can overcome most β-lactam resistance mechanisms
(including β-lactamases, porin mutations, and efflux pumps). Resistance is uncommon …

Background Cefiderocol is a last resort option for carbapenem-resistant (CR) Gram-negative
bacteria, especially metallo-β-lactamase (MBL)-producing Pseudomonas aeruginosa and …

Background Healthcare-associated infections involving Gram-negative bacteria (GNB) with
difficult-to-treat resistance (DTR) phenotype are associated with impaired patient-centered …

Antibacterial drug resistance of gram-negative bacteria (GNB) results in high morbidity and
mortality of GNB infection, seriously threaten human health globally. Developing new …

Evidence-based, standard antibiotic therapy for ventilator-associated pneumonia (VAP)
caused by carbapenem-resistant Acinetobacter baumannii (CRAB) is a relevant unmet …

Objectives To analyse the dynamics and mechanisms of stepwise resistance development
to cefiderocol in Pseudomonas aeruginosa. Methods Cefiderocol resistance evolution was …

Pseudomonas aeruginosa is the microorganism most frequently involved in the main ICU-
acquired infections, with special importance in ventilator associated pneumonia. Its …

Abstract Introduction Infections caused by Stenotrophomonas maltophilia are clinically
important due to its intrinsic resistance to a broad range of antibiotics. Therefore, selecting …

Cefiderocol is a novel synthetic siderophore-conjugated antibiotic that hijacks the bacterial
iron transport systems facilitating drug entry into cells, achieving high periplasmic …

Introduction New beta-lactams, associated or not with beta-lactamase inhibitors (NBs/BIs),
can respond to the spread of carbapenemase-producing enterobacteriales and …